Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 1.00 |
| ▸ | CA1 | P00915 | 12/20 | 1.00 |
| ▸ | CA12 | O43570 | 11/20 | 1.00 |
| ▸ | CA9 | Q16790 | 11/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 0.72 |
| ▸ | CA7 | P43166 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | GHSR | Q92847 | 1/20 | 0.63 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671936 | 0.94 | CA2 (1.00) | CA2CA1CA12CA9CA4 | |
| SCHEMBL15094124 | 0.86 | CA12 (0.74) | CA2CA1CA12CA9SMN1; SMN2 | |
| SCHEMBL607623 | 0.84 | CA2 (1.00) | CA2CA1CA12CA9CA4 | |
| SCHEMBL672109 | 0.82 | CA1 (1.00) | CA2CA1CA12CA9CA4 | |
| SCHEMBL4117293 | 0.82 | CA12 (0.68) | CA2CA1CA12CA9SMN1; SMN2 | |
| SCHEMBL15093703 | 0.81 | CA12 (0.73) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL28499329 | 0.81 | KMT2A (1.00) | CA2CA1CA12CA9CA4 | |
| SCHEMBL4107205 | 0.80 | TRPV1 (0.72) | CA2CA1CA12CA9SMN1; SMN2 | |
| SCHEMBL4112811 | 0.80 | CA12 (0.67) | CA2CA1CA12CA9SMN1; SMN2 | |
| SCHEMBL15093429 | 0.80 | CA12 (0.76) | CA2CA1CA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | claimed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | claimed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | claimed |
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-9962398-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2018-05-08 | — | — | US | disclosed |
| EP-3217970-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | Del Mar Pharmaceuticals (CA) | 2017-09-20 | — | — | EP | disclosed |
| EP-2590938-B1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC (CA) | 2017-06-07 | — | — | EP | disclosed |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC. (CA) | 2017-01-12 | — | — | US | disclosed |
| US-9463171-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2016-10-11 | — | — | US | disclosed |
| CN-103221388-B | For the novel sulfonamide compounds suppressing metastatic tumo(u)r to grow | 维理生物技术公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2016077264-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | DEL MAR PHARMACEUTICALS (CA) | 2016-05-19 | — | — | WO | disclosed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| CN-103221388-A | Novel sulfonamide compounds for inhibition of metastatic tumor growth | METASIGNAL THERAPEUTICS INC | 2013-07-24 | — | — | CN | disclosed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA2 5/4885CA1 31/4885CA12 61/4885 |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | MGMT, DCLRE1A, DNMT1 | CA2 4654/4885CA1 2097/4885CA12 1160/4885 |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA2 5/4885CA1 31/4885CA12 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.